ADVANCE Collaborative Group Selected Research

Gliclazide (Diamicron)

11/2019	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.
1/2019	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.
1/2019	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
1/2018	Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
1/2018	Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial.
1/2018	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON.
1/2017	Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus: The ADVANCE-ON Study.
1/2017	Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.
12/2016	Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
10/2016	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

ADVANCE Collaborative Group Research Topics

Disease

33	Type 2 Diabetes Mellitus (MODY) 01/2020 - 07/2005
28	Vascular Diseases (Vascular Disease) 11/2019 - 04/2007
3	Cardiovascular Diseases (Cardiovascular Disease) 11/2019 - 11/2010
3	Diabetes Complications 01/2018 - 02/2010
2	Diabetes Mellitus 01/2019 - 01/2018
2	Albuminuria 03/2013 - 11/2012
1	Stroke (Strokes) 01/2019
1	Myocardial Infarction 01/2019
1	Heart Failure 01/2017
1	Blindness (Hysterical Blindness) 01/2016
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2013
1	Diabetic Nephropathies (Diabetic Nephropathy) 11/2012
1	Atherosclerosis 11/2012
1	Atrial Fibrillation 06/2011
1	Hypertension (High Blood Pressure) 06/2011
1	Chronic Renal Insufficiency 12/2010
1	Erectile Dysfunction 11/2010
1	Hypoglycemia (Reactive Hypoglycemia) 10/2010

Drug/Important Bio-Agent (IBA)

27	Gliclazide (Diamicron)IBA 11/2019 - 04/2007
26	perindopril drug combination indapamideIBA 11/2019 - 04/2007
10	Perindopril FDA LinkGeneric 01/2019 - 01/2006
10	Indapamide FDA LinkGeneric 01/2019 - 01/2006
9	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 07/2005
5	CreatinineIBA 01/2019 - 06/2011
3	Biomarkers (Surrogate Marker)IBA 11/2019 - 01/2017
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 07/2005
2	AlbuminsIBA 01/2018 - 06/2011
2	Retinaldehyde (Retinal)IBA 10/2016 - 01/2016
2	HDL CholesterolIBA 11/2012 - 06/2011
1	8-Hydroxy-2'-DeoxyguanosineIBA 01/2018
1	pro-brain natriuretic peptide (1-76)IBA 01/2017
1	C-Reactive ProteinIBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2017
1	Troponin T (Troponin T1)IBA 01/2017
1	Receptor for Advanced Glycation End ProductsIBA 10/2015
1	Advanced Glycation End ProductsIBA 10/2015
1	Biological ProductsIBA 06/2011
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 06/2008
1	DiureticsIBA 07/2005

Therapy/Procedure

4	Therapeutics 01/2019 - 09/2007
3	Glycemic Control 09/2013 - 06/2008
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2019 - 11/2012
2	Light Coagulation 10/2016 - 01/2016
1	Surgical Amputation (Amputations) 01/2016
1	Kidney Transplantation 03/2013
1	Length of Stay 02/2010